Letter | Published:

The structure of a pseudo intercalated complex between actinomycin and the DNA binding sequence d(GpC)

Nature volume 296, pages 466469 (01 April 1982) | Download Citation

Subjects

Abstract

Actinomycin D (AMD) is used clinically to treat tumours such as Wilms' tumour1 and gestational choriocarcinoma2. It inhibits transcription in most cellular systems3,4, and binds to DNA, not to RNA3–5, with a preference for guanine6. The study of the crystal structure of a 2:1 complex between deoxyguanosine and AMD demonstrated both stacking and hydrogen-bonding interactions between the drug and the guanine ring7. Solution studies8,9 have indicated that the drug binds preferentially to guanine–pyrimidine sequences, such as d(GpC), and that an intercalated complex forms with both DNA10 and DNA fragments11. External binding12 and intercalation10,13 models for the structure of the complex between AMD and DNA have been proposed, but until now no crystal strucutre of a complex between AMD and an oligonucleotide has been reported. As the smallest unit of DNA with the potential for forming an intercalated duplex is a self-complementary deoxydinucleoside monophosphate, we undertook the crystallographic analysis of the 2:1 complex between deoxyguanylyl-3′, 5′-deoxycytidine, d(GpC), and AMD. The complex is found to form an unusual pseudo-intercalated structure.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    J. Am. med. Ass. 198, 826–836 (1966).

  2. 2.

    Cancer 30, 1517–1521 (1972).

  3. 3.

    & A. Rev. Biochem. 40, 775–810 (1971).

  4. 4.

    & in Inhibitors, of Nucleic Acid Synthesis, 40–66 (Springer, Berlin, 1974).

  5. 5.

    , , & Biochim. biophys. Acta 610, 241–247 (1980).

  6. 6.

    , & Proc. natn. Acad. Sci. U.S.A. 48, 2094–2101 (1962).

  7. 7.

    , , & Nature new Biol. 231, 200–205 (1971).

  8. 8.

    in Topics in Nucleic Acid Structure (ed. Neidle, S.) 197–217 (Macmillan, London, 1981).

  9. 9.

    & Biochemistry 14, 4912–4922 (1975).

  10. 10.

    & J. molec. Biol. 35, 251–290 (1968).

  11. 11.

    Biochemistry 13, 2396–2402 (1974).

  12. 12.

    , & Nature 198, 538–540 (1963).

  13. 13.

    & J. molec. Biol. 68, 21–34 (1972).

  14. 14.

    , & Acta crystallogr. A24, 351–359 (1968).

  15. 15.

    “DOCK” Interactive Three Dimensional Display and Manipulation of Molecular and Contour Data (ICR Internal Documentation, Philadelphia, 1981).

  16. 16.

    , , & J. molec. Biol. 104, 145–167 (1976).

  17. 17.

    , , , & J. molec. Biol. 104, 109–144 (1976).

  18. 18.

    , & J. molec. Biol. 114, 301–315 (1977).

  19. 19.

    et al. Nature 269, 304–307 (1977).

  20. 20.

    , , , & Nature 276, 471–474 (1978).

  21. 21.

    & A. Rev. Biophys. Bioengng 10, 87–114 (1981).

  22. 22.

    , & Nature 253, 324–326 (1975).

  23. 23.

    & Biochemistry 16, 2890–2895 (1977).

  24. 24.

    Biochim. biophys. Acta 442, 98–108 (1976).

  25. 25.

    Biopolymers 15, 533–558 (1976).

  26. 26.

    et al. Proc. natn. Acad. Sci. U.S.A. 77, 7204–7208 (1980).

  27. 27.

    & Biopolymers 18, 2905–2910 (1979).

  28. 28.

    & J. molec. Biol. 49, 319–342 (1970).

  29. 29.

    et al. J. med. Chem. 24, 1052–1059 (1981).

Download references

Author information

Affiliations

  1. Institute for Cancer Research, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, Pennsylvania 19111, USA

    • Fusao Takusagawa
    • , Michael Dabrow
    •  & Helen M. Berman
  2. Cancer Research Campaign Biomolecular Structure Research Group, Department of Biophysics, King's College, London WC2B 5RL, UK

    • Stephen Neidle

Authors

  1. Search for Fusao Takusagawa in:

  2. Search for Michael Dabrow in:

  3. Search for Stephen Neidle in:

  4. Search for Helen M. Berman in:

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/296466a0

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.